US approves India's Ranbaxy to make generic Lipitor
December 1, 2011 in MedicationsIndian pharmaceutical giant Ranbaxy won US regulatory approval to make the first generic version of cholesterol lowering drug Lipitor, a Pfizer product whose patent expired Wednesday.
Ranbaxy had faced delays in gaining US Food and Drug Administration approval due to problems with quality control at some of their Indian factories.
The FDA on Wednesday "approved the first generic version of the cholesterol-lowering drug Lipitor (atorvastatin calcium tablets)," an agency statement said.
"Ranbaxy Laboratories Ltd. has gained approval to make generic atorvastatin calcium tablets in 10 milligram, 20 mg, 40 mg, and 80 mg strengths. The drug will be manufactured by Ohm Laboratories in New Brunswick, New Jersey."
Lipitor was the best-selling drug of all-time, and earned Pfizer 100 billion dollars since coming on the market in 1997.
In the United States, anti-cholesterol drugs account for 255 million prescriptions a year, and about nine million people are taking Lipitor.
US-based Watson Pharmaceuticals earlier announced its launch of a generic version of Lipitor, atorvastatin calcium, under an exclusive supply and distribution agreement with Pfizer, whereby Pfizer manufactures the drug and Watson sells it, sharing net sales with Pfizer until 2016.
(c) 2011 AFP
-
Pfizer's blockbuster drug Lipitor goes generic
Nov 30, 2011 |
not rated yet |
0
-
Pfizer drug found with serious side effect
Nov 01, 2006 |
not rated yet |
0
-
Pfizer gets EU approval for kids' cholesterol drug
Jul 06, 2010 |
not rated yet |
0
-
Pfizer heart pill to be standalone therapy
Jul 26, 2006 |
not rated yet |
0
-
Pfizer maneuvers to protect Lipitor from generics
Nov 29, 2011 |
not rated yet |
0
-
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
May 25, 2012 |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (4) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
Potential Breakthrough in Seizure Control
13 hours ago
-
Popping/Cracked sternum.
18 hours ago
-
Which Mental Illness Encompasses This Problem?
18 hours ago
-
A question about drug tolerance
May 23, 2012
-
Poor nutrition leading to overeating?
May 23, 2012
-
Math and dyslexia?
May 21, 2012
- More from Physics Forums - Medical Sciences
More news stories
Missouri opts for untested drug for executions
(AP) -- The same anesthetic that caused the overdose death of pop star Michael Jackson is now the drug of choice for executions in Missouri, causing a stir among critics who question how the state can guarantee ...
Medications
May 24, 2012 |
not rated yet |
4
Aspirin may prevent recurrence of deep vein blood clots
(HealthDay) -- After suffering a type of blood clot called a venous thromboembolism, patients usually take a blood-thinner such as warfarin (Coumadin). But aspirin may do just as well after a period of time, ...
Medications
May 23, 2012 |
not rated yet |
2
|
Patients may receive too much acetaminophen in hospital
(HealthDay) -- Roughly 2.5 percent of admitted hospital patients may receive more than the safe daily cumulative dose of the pain-reliever acetaminophen, best known as Tylenol, on at least one day, according ...
Medications
May 23, 2012 |
1 / 5 (1) |
0
New quality standards limiting elemental impurities in medicines announced
As part of its ongoing efforts to help ensure the quality of medicines, the U.S. Pharmacopeial Convention (USP) has announced two new standards related to elemental impurities: General Chapters Elemental Impurities—Limits and ...
Medications
May 23, 2012 |
not rated yet |
0
Quality standards for heparin further strengthened
To help further secure a safe supply of the widely–used blood thinner heparin, a third round of revisions to quality standards for the drug has been advanced by the U.S. Pharmacopeial Convention (USP). USP's Expert Panel ...
Medications
May 23, 2012 |
not rated yet |
0
Travel to high altitudes tied to Crohn's, colitis flare-ups
(HealthDay) -- People with inflammatory bowel disease, which includes Crohn's disease and colitis, may be at increased risk for flare-ups when they fly or travel to high altitudes for skiing or mountain climbing, ...
Family history of Alzheimer's affects functional connectivity
(HealthDay) -- Cognitively normal individuals with a family history of late-onset Alzheimer's disease (AD) may display lower resting state functional connectivity in the default mode network (DMN) of the brain, ...
Transvaginal mesh op restores pelvic organ prolapse at price
(HealthDay) -- Transvaginal mesh (TVM) procedures are effective for anatomical restoration of pelvic organ prolapse (POP), but patients report a worsening of sexual function following surgery, according to ...
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...
Weight struggles? Blame new neurons in your hypothalamus
New nerve cells formed in a select part of the brain could hold considerable sway over how much you eat and consequently weigh, new animal research by Johns Hopkins scientists suggests in a study published in the May issue ...
Thioridazine kills cancer stem cells in human while avoiding toxic side-effects of conventional cancer treatments
A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments.
